Esperion Announces Proposed Public Offering
ANN ARBOR, Mich., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) ("Esperion" or the "Company"), today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock (or common stock ...
December 3, 2021
by FirstWordPharma
NEWS SEC-MS: a “powerful tool” for ADC analysis, find researchers
In a new study, scientists demonstrated that size exclusion chromatography (SEC) could be successfully combined with mass spectrometry (MS) to characterise antibody-drug conjugates (ADCs) on the intact molecular level.
October 28, 2021
by EuropeanPharmaceuticalReview
Clovis Oncology Announces Renewal of At-The-Market Equity Offering Program
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission ("SEC") to renew its previously established ATM facility under which it may offer and sell additional shares.
August 17, 2021
by firstwordpharma
Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) today announced closing of its previously announced underwritten public offering of 7,590,000 shares of its common stock at a public offering price of $19.00 per share
August 17, 2021
by firstwordpharma
The Securities and Exchange Commission Declared Cellect Biotechnology’s Registration Statement Filed on Form F-4 Effective in Connection with its Previously Announced Strategic Merger with Quoin Pharm
Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the functional selection of stem cells, announced that its registration statement filed on Form F-4 with Securities and Exchange Commission ("SEC") on August 10
August 16, 2021
by firstwordpharma
EyeGate Announces Closing of $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
EyeGate Pharmaceuticals, Inc. today announced the closing of its previously announced registered direct offering priced at-the-marked under Nasdaq rules of 4,668,844 shares of its common stock at a purchase price of $2.3025 per share.
August 12, 2021
by firstwordpharma
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. All of the shares are being offered by Fulcrum.
August 11, 2021
by firstwordpharma
Alpha Healthcare Acquisition Corp. Sets August 24, 2021, for Special Shareholder Meeting to Vote on Humacyte Business Combination
Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) ("AHAC"), a special purpose acquisition company, today announced that it has filed a definitive proxy statement with the Securities and Exchange Commission ("SEC") and set a date of August 24, 2021.
August 5, 2021
by firstwordpharma
Icosavax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases.
August 3, 2021
by firstwordpharma
Avidity Biosciences Announces Proposed Public Offering of Common Stock
Avidity Biosciences, Inc. (Nasdaq: RNA) today announced that it intends to offer and sell, subject to market and other conditions, $100 million of shares of its common stock in an underwritten public offering.
August 3, 2021
by firstwordpharma
MiNK Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
MiNK Therapeutics today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of its common stock.
July 29, 2021
by firstwordpharma
AzurRx BioPharma Announces Closing of $5.75 Million Bought Deal Offering and Exercise in Full of Underwriter’s Option to Purchase Additional Shares
AzurRx BioPharma, Inc. announced today the closing of its previously announced underwritten public offering of 10,454,546 shares of common stock of the Company.
July 28, 2021
by firstwordpharma